The DOI matches its Crossref record.
Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic Disease)
Abstract
BACKGROUND: Neuromyelitis optica is a severe demyelinating disease that selectively involves the optic nerves and the spinal cord but usually spares the brain. It is considered to have a B-cell-induced pathogenesis. Mitoxantrone hydrochloride, a synthetic anthracenedione approved for worsening relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis, has been shown to primarily suppress the humoral response. OBJECTIVE: To evaluate the benefit of mitoxantrone treatment in patients with relapsing neuromyelitis optica. DESIGN: Prospective 2-year study. SETTING: Academic multiple sclerosis center. PATIENTS: Five patients (3 women and 2 men) with an age range of 20 to 51 years and an Expanded Disability Status Scale score of 2.5 to 6.5 (mean +/- SD, 4.40 +/- 1.88). INTERVENTIONS: Monthly intravenous infusions of mitoxantrone hydrochloride, 12 mg/m2, for 6 months followed by 3 additional treatments every 3 months. MAIN OUTCOME MEASURES: Expanded Disability Status Scale score measured every 3 months and during relapses; findings on orbital, brain, and spinal cord magnetic resonance images performed at baseline and at 3, 6, 12, 18, and 24 months; and visual evoked potentials and results of ophthalmologic evaluations performed at baseline and annually. RESULTS: During the 2 years of treatment, 2 patients each had a relapse once within the initial 5 months of treatment (1 severe and 1 moderate). Improvement was seen clinically and on magnetic resonance images in 4 patients. Patients generally tolerated the treatment well, although 1 patient had a reversible decrease in cardiac ejection fraction. CONCLUSION: Our results suggest a beneficial effect of mitoxantrone treatment for relapsing neuromyelitis optica.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The spectrum of neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Lucchinetti, C. F., Pittock, S. J., & Weinshenker, B. G. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70216-8 · Cited by 2,179
Jarius, S., Paul, F., Weinshenker, B. G., Levy, M., Kim, H. J., & Wildemann, B. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0214-9 · Cited by 478
EFNS guidelines on diagnosis and management of neuromyelitis optica
Sellner, J., Boggild, M., Clanet, M., Hintzen, R. Q., Illes, Z., Montalban, X., Du Pasquier, R. A., Polman, C. H., Sorensen, P. S., & Hemmer, B. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03066.x · Cited by 461
Treatment of Neuromyelitis Optica With Rituximab: Retrospective Analysis of 25 Patients
(2008) · Archives of Neurology · doi:10.1001/archneur.65.11.noc80069 · Cited by 459
Neuromyelitis optica: clinical features, immunopathogenesis and treatment
Jarius, S., Wildemann, B., & Paul, F. (2014) · Clinical and Experimental Immunology · doi:10.1111/cei.12271 · Cited by 342
Metadata
- Authors
- Weinstock-Guttman, B., Ramanathan, M., Lincoff, N., Napoli, S. Q., Sharma, J., Feichter, J., & Bakshi, R.
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2006-07-01
- Volume
- 63
- Issue
- 7
- Pages
- 957
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W1998029081
- Cited by
- 174
- References
- 0
- FWCI
- 10.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic Disease). https://app.cochat.ai/papers/10.1001/archneur.63.7.957
- The paper
- Weinstock-Guttman, B., Ramanathan, M., Lincoff, N., Napoli, S. Q., Sharma, J., Feichter, J., & Bakshi, R. (2006). Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic Disease). Archives of Neurology. https://doi.org/10.1001/archneur.63.7.957
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.